To investigate the effect of remote and proximate cancer on hepatic protein metabolism, we determined rates of total protein synthesis by hepatocytes (HPS) isolated from 31 patients undergoing liver wedge biopsy: 7 patients with benign disease, 14 with gastric cancer, and 10 with colorectal cancer (5 of whom had liver metastases).
Introduction
Alterations of protein metabolism have been demonstrated in the presence of malignancy. Most studies have found higher rates of whole body protein metabolism in cancer patients compared with patients with benign disease when appropriately controlled for nutritional status and weight loss (1) (2) (3) (4) (5) (6) . Because the liver plays a central role in control ofintermediary metabolism, we believed it would be important to examine the in vitro hepatic contribution to the higher whole body protein flux found with in vivo studies of patients with cancer. Studies in animal models of malignancy have shown conflicting results in measuring the effects of cancer on hepatic protein synthesis (7) (8) (9) (10) , and only one previous study has been able to address this question directly in man (1 1) .
A technique for obtaining a viable suspension of isolated hepatocytes from adult rat liver was originally introduced by Berry and Friend (12) and modified by Seglen (13). Bourel et al. (14) had isolated human hepatocytes from needle biopsy specimens and Strom et al. (15) showed that the collagenase perfusion technique could be applied to human liver obtainable from surgical procedures.
The present investigation was undertaken to examine the relative contribution of malignancy and nutritional status to hepatic protein synthesis in man. Rates oftotal protein synthesis were studied in hepatocytes isolated from patients with a variety of malignancies and differing antecedent nutritional status.
Methods
Patients. 31 patients were studied; 15 male and 16 female, ranging in age from 29 to 79 yr with a mean of 56.5±3 yr. Table I lists the pathological diagnoses for patients with malignant and benign disease. Table II provides information on the extent of disease in the patients studied: histological lymph node involvement and presence of metastatic disease. We excluded patients with diabetes, sepsis, and those receiving nutritional support because of the metabolic changes known to occur in these states. All patients were evaluated and treated at Memorial Sloan-Kettering Cancer Center (MSKCC). The protocol followed for obtaining human specimens was approved by the MSKCC Institutional Review Board, although all patients with malignancy were undergoing liver biopsy for staging or diagnosis.
A dietary history was obtained from each patient. An index of nutritional status was taken as the percent body weight loss upon admission to hospital (one minus the actual body weight on admission divided by the usual weight before illness). The serum albumin and total protein levels taken preoperatively are given in Table II. The patients, fasted for 8-10 h before the operation, were premedicated with meperidine (50-75 mg i.m.), hydroxyzine (50-75 mg i.m.), and glycopyrrolate (0.2 mg i.m.) and administered anesthetic agents as combinations of nitrous oxide, narcotic, or the inhalational agent isoflurane. Blood samples were taken just after anesthesia began and analyzed for the acute phase protein, C-reactive protein (CRP)' by radial immunodiffusion (Calbiochem, Behring Diagnostic, La Jolla, CA), insulin, glucagon, and cortisol by radioimmunoassay (insulin and cortisol kits from Diagnostic Products, Inc., Los Angeles, CA, and glucagon kits from Cambridge Medical Diagnostics, Billerica, MA), serum albumin and total protein using computerized sequential multiple analysis equipment (Technicon Instruments Co, Tarrytown, NY), and lactate dehydrogenase (LDH) levels were determined spectrophotometrically using a centrifugal chemical analyzer (Multistat Plus, Instrumentation Laboratories, Lexington, MA).
Hepatocyte isolation. Liver wedge biopsies (2-7 g) were obtained soon after the abdominal cavity was opened. Areas of liver without metastases were biopsied and separate specimens were sent for formal histological examination. The orifices of all hepatic vessels in the liver biopsy were immediately flushed with ice-cold electrolyte solution for kidney preservation (Travenol Laboratories, Deerfield, IL) with 30 g added dextrose per liter. This procedure removed clots from the vessels to facilitate the perfusion. The specimen was then transported to the laboratory in the same solution. A two-step method of collagenase perfusion (14) was used for hepatocyte isolation. Plastic polyethylene catheters (18-and 20-gauge) were inserted into three to six vascular orifices on the cut surface ofthe liver specimen. A 45-60-min perfusion with calcium-free buffer was performed at 370C at a flow rate of 10 ml/min per catheter. Calciumfree buffer was prepared as 145 mM NaCI, 7 mM KCI, and 10 mM Hepes from Boehringer Mannheim Biochemicals, Indianapolis, IN, to which 4 mM dextrose and 0.25% bovine serum albumin was added (pH 7.4). This perfusion was followed by a 60-min collagenase perfusion at 370C with 0. 5 The cells were then sedimented by centrifugation at 50 g for 4 min at room temperature, the supernatant discarded, and the hepatocytes resuspended in incubation medium, described in the next section.
With this procedure, viability, assessed by trypan blue exclusion for all 31 patients studied, was 65±2% before incubation. In parallel experiments, viability of human hepatocytes in an additional nine patients was assessed by trypan blue exclusion as well as by measurement of cytoplasmic enzyme leakage (LDH release) (16) . The fraction of cellular L.DH released into the supernatant of the incubation media was determined arid found to be 2.1±0.4% over 60 min in nine patients. Between 2 and 50 X 106 cells were isolated per biopsy specimen and the mean total yield was 17±2 X 106 cells per specimen.
Measurement of valine incorporation into proteins. Total cellular and secreted protein synthesis during I h was assayed as U-4C-valine incorporation into TCA-insoluble material, as previously described (10) . The assay was initiated by the addition of the cells to ;an incubation mixture at 379C containing U-'4C-valine (5 mM, 0.4 MCi/mol), sodium pyrpvate (20 mM) as an energy source, and 19 amino acids at physiological concentrations, giving a final volume of 3.03 ml. The mean cell count for the assay was 3.0±0.4 X 106 cells/ml.
Aliquots ofcells and medium were removed at timed intervals of0, 30, and 60 min; TCA was added to a final concentration of 5% wt/vol. The precipitates were stored at 40C for over I h, then collected on 0.45 AM nitrocellulose filters and washed copiously with ice-cold 5% TCA, and counted in 10 ml Biofluor (New England Nuclear, Boston, MA) using a Tricarb liquid scintillation counter (Packard Instrument Co., Inc., Downers Grove, IL). Internal standards were used for counting efficiency calculations.
Rates of incorporation of radioactivity into TCA-precipitable material (dpm/h per 105 viable cells) were divided by the specific activity of valine in the incubation medium to determine the amount of valine incorporated. In this technique of using high concentrations of valine, extracellular, intracellular, and amino-acylated transfer RNA pools have been shown to equilibrate rapidly and the extracellular specific radioactivity can be used as the immediate protein precursor pool specific activity ( 17) .
Statistics. All data were presented as the mean±SE. Statistical comparisons were made using the nonparametric Kruskal-Wallis test. Significance, in all cases, was designated at the 5% level. Linear regression analysis was performed by the method of least squares (18).
Results
Valine was incorporated into TCA-insoluble material by isolated hepatocytes from liver biopsy specimens in a linear fashion over 60 min. The mean hepatocyte viability, as assessed by Table III , we did find that hepatocytes from patients with colorectal cancer without liver metastases had somewhat lower viability, as assessed by trypan blue exclusion, than those patients with colorectal cancer who had liver metastases. However, this difference was not statistically significant, nor were any other statistically significant differences found among the varying groups of patients in cell viability as determined by trypan blue exclusion in all 31 patients. In parallel experiments, cell viability as measured as fraction of LDH released from hepatocytes over 1 h was found to be 1.9±0.6% in six patients with malignancy and three patients with benign disease had an LDH release of 2.3±0.4%. No significant differences in either trypan blue exclusion or LDH release were found in hepatocytes from the patients with benign disease as compared with those with malignancy. Both the mean cell count used in the assay and the total yield of hepatocytes were somewhat lower in patients with benign disease, but this was not a statistically significant difference.
Levels of CRP in plasma taken simultaneously with the liver wedge biopsies were higher in non-weight-losing cancer patients than in patients with benign disease and equivalent nutritional status, although this difference did not reach statistical significance (Table IV) . No differences were seen between weight-losing and non-weight-losing gastric cancer patients. The highest levels ofCRP were found in patients with colorectal cancer metastatic to the liver. Patients with colorectal cancer with hepatic metastases had significantly higher plasma levels of CRP than patients with colorectal cancer without liver metastases (P < 0.05).
Serum and plasma hormone levels are also shown in Table  IV . Neither serum insulin nor plasma glucagon levels were found to be correlated with rates of hepatocyte protein synthesis (r = -0.07 and r = 0.20, respectively by linear regression). In patients with equivalent nutritional status, plasma cortisol levels were elevated in the patients with malignancies (22.6±1.9 mg/dl) when compared with patients with benign disease (13.3±2.8 mg/dl; P < 0.02). No differences were found between the group of patients with malignancies without weight loss and the group with benign disease with respect to the time of day that the serum was collected for the cortisol levels.
Discussion
Studies of whole-body metabolism in man have shown abnormalities in states of malnutrition and malignancy. Although reports of whole-body protein metabolism have shown conflicting results, many studies have found higher rates of whole-body protein turnover, synthesis, and catabolism in cancer patients when compared with patients with benign disease appropriately matched as to nutritional status, weight loss, and age (1) (2) (3) (4) (5) (6) . Clinically malnourished or starvationadapted normal subjects generally have been found to have low rates of whole-body protein turnover (1, 19) .
It was our goal to develop a technique for assessing the contribution of the liver to these metabolic changes shown on the whole-body level in malnutrition and malignancy in man.
The present report demonstrates that significant numbers of The relationship between protein synthetic rates by freshly isolated hepatocytes as in our techniques and by the intact liver in vivo has been examined in several studies in animal models. In a comparison of hepatic protein synthesis in vivo using a flooding dose of tracer amino acid in a rat sarcoma model with in vitro measurements using freshly isolated hepatocytes, increased protein synthesis has been shown using both methods (20) . However, the degree of stimulation seen was greater in the in vitro assay than in the in vivo method. Fornander et al. (21) showed a close correlation between in vivo protein synthesis using the flooding dose methods and in vitro liver slice method in an animal model of liver ischemia.
We have demonstrated that protein synthesis in hepatocytes isolated from cancer patients is higher than that from patients with benign disease with similar nutritional status and body weight loss. This same relationship was found for two different types of gastrointestinal malignancies: gastric and colorectal adenocarcinoma or lymphoma. It has not been determined from the present study what rates of hepatic protein synthesis would be obtained in patients with cancers outside the gastrointestinal tract. Several studies have examined the role of liver protein synthesis in mice or rats with an implanted tumor. In general, these animal studies have shown increases in hepatic protein synthesis in malignancy where the animals have lost minimal actual weight (carcass weight) (7) (8) (9) (10) . It has been shown that techniques for measuring the rate of protein synthesis in vivo in a rapidly turning over tissue such as the liver must minimize the problem of assessing the correct precursor amino acid pool specific radioactivity and possible reutilization of label during the experiment (22). McNurlan and Garlick developed a technique for minimizing these problems by using a flooding dose of labeled amino acid precursor and by measuring the specific radioactivity of the precursor pool of free amino acid. Pain et al. (7) , using this method in a mouse ascites tumor model, showed an increase in fractional rates of liver protein synthesis in comparison with pair-fed control animals. However, Emery et al. (8) , using the same flooding dose amino acid technique, found a reduction in liver protein synthesis in mice with an implanted hypernephroma. It is interesting to note that in this model the tumor-bearing mice lost 20% of their body weight. These authors found that normal mice fasted for several days had a fall in protein synthesis in liver as severe as that observed in the tumor-bearing mice. Warren et al. (9) , using isolated hepatocytes exposed to a high concentration of precursor amino acid, found an increase in total hepatocyte protein synthesis rates from rats bearing an implanted methylcholanthrene-induced sarcoma. In this study, the carcass weight (body weight minus tumor weight) for the tumor-bearing rats was < 5% lower than the carcass weight of the pair-fed control rats. In general in these animal studies, increases in liver protein synthesis have been demonstrated in malignancy where actual carcass weight is minimally decreased. We obtained similar results in our human hepatocyte studies.
Rates of human liver protein synthesis were examined using a liver slice technique by Lundholm et al. (1 1). Liver slices, of thickness 0.4 mm, were made from specimens obtained from patients. Incorporation of leucine was measured using a high concentration of amino acids. These authors found an increased rate of protein synthesis in cancer patients compared with healthy control subjects. No mention was made in this study of nutritional status, body weight loss, or stage of tumor in these patients. Using the same liver slice technique, they found also an increased liver protein synthesis in mice bearing an implanted sarcoma.
We found a relationship between hepatocyte protein synthesis and percent body weight loss. Patients with > 5% body weight loss had reduced liver protein synthesis. Studies in rat have shown depression of hepatic protein synthesis (as a percent of the protein pool synthesized per day) both in starvation and in protein deprivation when an appropriately large dose tracer method is used (22-24).
We found elevated rates of hepatocyte protein synthesis in patients with colorectal carcinoma with liver metastases compared with those without liver metastases. Carmichael et al. (2) , measured whole-body protein kinetics in patients with colorectal carcinoma using isotopic leucine tracer techniques. These authors found increased rates of whole-body protein turnover, synthesis, and breakdown in patients with Dukes D colorectal carcinoma (distant metastases, generally to the liver). For our study, the increased rates of hepatocyte protein synthesis in patients with metastatic liver disease may perhaps be related to the volume of tumor burden or perhaps to the quantity of normal liver tissue that remains for synthesizing protein.
To investigate possible qualitative changes in specific proteins being made by the liver in cancer and in differing nutritional states we examined levels of the acute-phase protein, CRP, in the sera from the patients we studied. Acute-phase proteins are increased in response to many forms of tissue injury, inflammation, infection, and cancer (25, 26) . We found the highest CRP levels in patients with colorectal cancer metastatic to the liver and these levels were higher than those found in patients with colorectal cancer without hepatic metastases. The higher levels of protein synthesis in hepatocytes from patients with hepatic metastases from colorectal primary carcinoma may reflect, in part, higher rates of synthesis of acute-phase proteins such as CRP.
Alterations in levels of several hormones have been demonstrated in the settings of both malignancy and malnutrition (1-6). In samples obtained from patients at the onset of anesthesia after an overnight fast, we found no significant differences in either serum insulin or plasma glucagon levels that reflected changes we saw in hepatic protein synthesis. Insulin is known to stimulate hepatic protein synthesis (27) , but serum insulin levels in rats with tumors have not been uniformly consistent (1, 9, 27) . Glucagon stimulates autophagic degradation of liver protein, particularly by affecting the intracellular amino acid supply (28). However, glucagon has been shown to inhibit protein synthesis in liver in rat studies (29) . Perhaps a more likely possibility is stimulation of hepatic protein synthesis by glucocorticoids; cortisol has well-established effects on protein synthesis in liver (30) . Increased cortisol levels have been observed in tumor-bearing humans compared with patients with benign surgical diseases (31) . We found that patients with malignancies had higher plasma cortisol levels than those with benign disease.
Recently attention has been focused on products of activated macrophages producing metabolic alterations in chronic disease states (32-34). Tumor necrosis factor (TNF) has been shown to stimulate certain hepatic proteins and spontaneous elaboration of TNF by peripheral blood monocytes isolated from cancer patients has recently been demonstrated (35) , indicating that endogenous TNF production may occur as part of the host's response to cancer. Other factors known to stimulate hepatic protein synthesis include interleukin-1 and hepatocyte-stimulating factors (36, 37) . None of these mediators has been measured in the sera of patients with cachexia of chronic illness (34) or of cancer (38) , and therefore their relative contributions to the metabolic disturbances of cancer cachexia remain a matter of speculation. Further work is in progress to elucidate the role of these hormones or other factors in mediating the effects of malignancy and malnutrition on host protein metabolism.
This study has shown alterations in hepatic protein synthesis in malignancy in man. However, the extent 
